Beam Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics R&D Spending Growth & History (BEAM)
Beam Therapeutics's r&d spending was $409.6M for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $409.6M | $42.1M | +11.44% |
| 2024 | 2024-12-31 | $367.6M | −$69.8M | −15.96% |
| 2023 | 2023-12-31 | $437.4M | $125.8M | +40.37% |
| 2022 | 2022-12-31 | $311.6M | −$75.5M | −19.50% |
| 2021 | 2021-12-31 | $387.1M | $283.9M | +275.16% |
| 2020 | 2020-12-31 | $103.2M | $48.6M | +88.91% |
| 2019 | 2019-12-31 | $54.6M | — | — |
Beam Therapeutics quarterly r&d spending
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $95.1M | −$6.7M | −6.55% |
| Q1 2026 | 2026-03-31 | $104.5M | $5.7M | +5.78% |
| Q4 2025 | 2025-12-31 | $99.3M | −$2.2M | −2.14% |
| Q3 2025 | 2025-09-30 | $109.8M | $15.5M | +16.46% |
| Q2 2025 | 2025-06-30 | $101.8M | $14.7M | +16.91% |
| Q1 2025 | 2025-03-31 | $98.8M | $14.0M | +16.50% |
| Q4 2024 | 2024-12-31 | $101.4M | −$38.6M | −27.58% |
| Q3 2024 | 2024-09-30 | $94.3M | −$5.8M | −5.79% |
| Q2 2024 | 2024-06-30 | $87.0M | −$10.6M | −10.83% |
| Q1 2024 | 2024-03-31 | $84.8M | −$14.8M | −14.88% |
| Q4 2023 | 2023-12-31 | $140.1M | $53.7M | +62.24% |
| Q3 2023 | 2023-09-30 | $100.0M | $14.8M | +17.31% |
| Q2 2023 | 2023-06-30 | $97.6M | $23.1M | +30.92% |
| Q1 2023 | 2023-03-31 | $99.6M | $34.2M | +52.34% |
| Q4 2022 | 2022-12-31 | $86.3M | −$10.4M | −10.79% |
| Q3 2022 | 2022-09-30 | $85.3M | $30.7M | +56.14% |
| Q2 2022 | 2022-06-30 | $74.6M | $29.0M | +63.58% |
| Q1 2022 | 2022-03-31 | $65.4M | −$124.7M | −65.59% |
| Q4 2021 | 2021-12-31 | $96.8M | $64.3M | +198.24% |
| Q3 2021 | 2021-09-30 | $54.6M | $24.8M | +83.15% |
| Q2 2021 | 2021-06-30 | $45.6M | $26.2M | +135.49% |
| Q1 2021 | 2021-03-31 | $190.1M | $168.6M | +782.20% |
| Q4 2020 | 2020-12-31 | $32.5M | $12.2M | +60.51% |
| Q3 2020 | 2020-09-30 | $29.8M | $17.3M | +137.78% |
| Q2 2020 | 2020-06-30 | $19.4M | $6.7M | +52.63% |
| Q1 2020 | 2020-03-31 | $21.5M | $12.4M | +134.76% |
| Q4 2019 | 2019-12-31 | $20.2M | — | — |
| Q3 2019 | 2019-09-30 | $12.5M | — | — |
| Q2 2019 | 2019-06-30 | $12.7M | — | — |
| Q1 2019 | 2019-03-31 | $9.2M | — | — |
Beam Therapeutics r&d spending trends
Over the last five fiscal years, Beam Therapeutics's r&d spending increased from $103.2M to $409.6M, a change of $306.4M. The latest reported quarter, Q2 2026, shows $95.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...